Based on RUCDR Infinite Biologics, which was founded in 1999 to provide biobanking services and biomaterials to advance the genetic disease research of partners in the public and private sectors. Following the spinout, Infinity Biologix said it will provide sample collection, processing, storage, and analytical services integrated with scientific and technical support in both the research and clinical arenas.
COVID-19: COVID-19 Saliva test. In April 2020, IBX (formerly Rutgers RUCDR Infinite Biologics) received the first FDA Emergency Use Authorization (EUA) enabling the use of saliva tests to detect the presence of the SARS-CoV-2 coronavirus. Since then, a revised EUA for an at-home saliva sample collection was also approved.